601 264 6000
South Mississippi's Largest Multi-Specialty Clinic

Hattiesburg Clinic

Memory Center - Research Trials

The Memory Center conducts clinical trials that focus on neurological therapeutics, with Alzheimer’s disease being an area of special interest and expertise. Basic research techniques generate ideas about which medical strategies may be likely to help alleviate symptoms of an illness or disease. Clinical research protocols are then developed in order to test these hypotheses.

Memory Center – Research Trials

Clinical trials are designed to determine if a new treatment will be both safe and effective for patients. In addition, trials will often collect data to determine whether an investigational strategy will have a broader influence on related problems such as activities of daily living, caregiver stress or general quality of life.

Clinical trials in Alzheimer’s disease will usually involve both patients and caregivers. While trial participation is completely voluntary, it is important to recognize the time and effort involved in the successful completion of a clinical trial.

The Memory Center is gratified to be able to offer our community access to potential new treatments for Alzheimer’s. New treatments can only be discovered through the partnership of patient volunteers, research sites, and scientific sponsors. Everyone plays an important role in this investigational process. Every day, we work with hopeful optimism towards more effective therapies, more accurate diagnoses, and eventually a sustainable cure for Alzheimer’s disease.

None of this happens without your help.


Clarity AD (BAN2401-G000-301) NCT03887455

  • This study will be conducted to evaluate the efficacy of BAN2401 in participants with early Alzheimer’s disease (EAD) by determining the superiority of BAN2401 compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This study will also evaluate the long-term safety and tolerability of BAN2401 in participants with EAD in the Extension Phase and whether the long-term effects of BAN2401 as measured by the CDR-SB at the end of the Core Study is maintained over time in the Extension Phase.
  • For more information please visit clarityadstudy.com

HOPE4MCI (AGB101 MCD) Identifier: NCT03486938

  • The primary objective of the study is to evaluate the efficacy of AGB101 on slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with mild cognitive impairment due to Alzheimer’s Disease (MCI due to AD) also known as prodromal AD. Participants will be randomized to receive placebo or AGB101 (220 mg), once daily for 78 weeks. Secondary objectives are to assess the effect of AGB101 compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE) and Functional Activities Questionnaire (FAQ).
  • For more information, visit hope4mci.org


AWARE Study (M15-566) NCT02880956

  • A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer’s Disease
  • The Aware Study is evaluating an investigational medication that targets a protein called tau, which builds-up in the brains of people with Early Alzheimer’s disease.
  • For more information, visit www.theawarestudy.com

elevage (TTP488-305) Identifier: NCT03980730

  • This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer’s disease and impaired glucose tolerance. Patients will receive either azeliragon or placebo with a patient’s participation lasting approximately 9 months (in Part 1) or 21 months (in Part 2).

EMBARK (221AD304) NCT04241068

  • Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer’s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

H8A-US-B004 (GERAS-US) Identifier: NCT02951598

  • The purpose of this study is to learn about health care use, costs, and clinical outcomes over time for amyloid positive participants with early stages of AD in the United States. This study is for research purposes only, and is not intended to treat any medical condition. No study therapy(ies) for AD will be administered

The GAIN Trial (COR388-010) Identifier: NCT03823404

  • This is a randomized, double-blind, placebo-controlled study that will assess the efficacy, safety, and tolerability of 2 dose levels of COR388 in subjects with a clinical diagnosis of mild to moderate AD dementia.
  • For more information, visit www.gaintrial.com

The Memory Center provides patients in south Mississippi with access to leading-edge clinical trials and care for those suffering with Alzheimer’s disease, dementia and other cognitive impairment disorders. By partnering with both academia and industry, the Memory Center is able to integrate research studies into the flow of clinical neurology practice. 


Why Participate?


Common Questions


Alzheimer’s Research


Participating in Alzheimer’s Research


Memory Center Logo


    Caregiver Name (if applicable)

    Patient Name (if applicable)

    Patient Date of Birth (if applicable)

    Your Email (required)

    Your Phone (required)

    Please check the box below:

    I agree for a representative from Hattiesburg Clinic Memory Center to contact me.

    Your Message

    Please do not use this contact form to send any messages requiring urgent attention. For urgent medical matters, contact your doctor’s office or visit the nearest emergency room. This messaging system is monitored only during normal business hours. It is not monitored after hours or on holidays.


    Ronald L. Schwartz, MD, CPI

    Ronald L. Schwartz, MD, CPI


    (601) 579-5016


    415 South 28th Ave.
    Main Clinic – 6th Floor
    Hattiesburg, MS 39401


    Monday – Friday
    8:00 a.m. – 5:00 p.m.